CARVYKTI ® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement
CARVYKTI
®
is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy
RARITAN, N.J., (July 2, 2024)
– Johnson & Johnson...
Zur Pressemeldung auf www.jnj.com